CD19 and neoplasm: Efforts to overcome primary or secondary resistance thus include multi or tandem CAR T cells targeting two different tumor antigens (e. g., CD19 and CD22) [19], or the use of checkpoint inhibitors [20] or interleukin-15 [21] to reactivate exhausted CAR T cells.